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Abstract
Background: MicroRNAs (miRNAs) are a novel class of powerful, endogenous regulators of gene expression. This
study was designed to ascertain if miR-30a is involved in the cardioprotective actions of salvianolic acid B (Sal B)
against myocardial ischemia–reperfusion (I–R) injury through suppression of autophagy.
Methods: Murine myocardial cells that had undergone primary culture were induced by I–R and incubated with
Sal B (25, 50, 100 μM) in the presence of a miR-30a mimic or miR-30a inhibitor. Expression of miR-30a, beclin-1,
LC3-II and p-Akt protein, cell viability, and lactic acid dehydrogenase (LDH) release were assessed.
Results: miR-30a expression was down-regulated remarkably in I–R cells, and this suppression could be reversed by
Sal B in a dose-dependent manner. Sal B repressed autophagy in I–R myocardial cells. Sal B improved cell viability
and reduced the rate of LDH leakage, which suggested that autophagy suppression was beneficial for cell survival.
Knockdown of miR-30a with a miR-30a inhibitor could reverse the anti-autophagy effect of Sal B against I–R injury.
Furthermore, we confirmed that Sal B has a protective role in miR-30a-mediated autophagy through the PI3K/Akt
signaling pathway, which was abrogated by the PI3K inhibitor LY294002.
Conclusions: These data suggest that miR-30a is involved in Sal B-mediated cardioprotection against I–R injury
through the PI3K/Akt signaling pathway.
Keywords: Ischemic heart disease, Salvianolic acid B, Autophagy, miR-30a
Abbreviations: CCK-8, Cell counting kit 8; I/R, Ischemia/reperfusion; LDH, Lactic acid dehydrogenase;
miRNA, MicroRNA; PI3K, Phosphoinositide 3-kinase; Sal B, Salvianolic acid B
Background
Despite optimal treatment, ischemic heart disease - is
the leading cause of death worldwide [1], and the sec-
ond leading cause of cardiovascular death in China
[2]. Treatment for myocardial ischemia includes
cholesterol-lowering medications, beta-blockers, nitro-
glycerin, and calcium antagonists [3–5]. Such treat-
ment can attenuate myocardial infarction, reduce
cardiomyocyte apoptosis and restore contractile
dysfunction. Recently, constituents from natural herbs
have attracted attention with regard to pharmaceutical
development.
MicroRNAs (miRNAs) are endogenous small RNA
molecules best known for post-transcriptional gene
regulation. MiR-30a is a member of the miR-30 family,
which was identified significantly altered miRNAs in
mice cardiac tissue with a model of myocardial I/R com-
pared with normal cardiac tissue in our previous study.
Other Studies also reported that miR-30a was found to
be one of the differentially expressed miRNAs involved
in cardiovascular pathophysiology [6–9].
Autophagy is a highly conserved cellular mechanism
that plays a key part in the turnover of long-lived pro-
teins, RNA, and dysfunctional organelles [10]. In mouse
hearts [11] and isolated rabbit hearts [12], autophagy
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can be induced by ischemia and enhanced further by
reperfusion. Activation of autophagy is reflected by an
increase in the abundance of key proteins of autophagy-
related pathways: beclin-1, light chain 3 (LC3),
autophagy-related gene 5-12 complex (ATG5-12), and
p62 [13–15]. Therefore, regulation of autophagy by
pharmacologic approaches is a potential strategy to treat
heart diseases. In recent years,the close relationship
between miR-30a and autophagy has been observed..
Studies have shown that miR-30a can negatively regulate
expression of the beclin-1 gene, resulting in decreased
autophagic activity in cancer cell lines such as T98G,
MDA-MB-468 and H1299 [16]. Circulating miR-30 has
been shown to be positively associated with left ventricu-
lar wall thickness, and regarded to be an important
marker for the diagnosis of left ventricular hypertrophy
due to miR-30a-induced alterations in expression of the
beclin-1 gene and autophagy in cardiomyocytes [8].
Activation of the phosphoinositide 3-kinase (PI3K)/Akt
signaling pathway, which could inhibit autophagy, is
related to cardiomyocyte protection [17]. Hu et al. [18].
also reported that inhibition of the PI3K/Akt signaling
pathway could abolish the effects of B-type natriuretic
peptide on myocardial ischemia–reperfusion (I–R) in-
jury. It has been reported that PI3K catalytic subunit
delta is a direct target of miR-30a because miR-30a binds
directly to the 3′-UTR of PI3K catalytic subunit delta
mRNA [19]. In addition, the PI3K/ Akt) the mammalian
target of Rapamycin (mTOR) signalling pathway nega-
tively regulate autophagy under certain conditions [20].
Salvianolic acid B (Sal B) is the most important and
abundant bioactive component of the traditional
Chinese herb Salvia miltiorrhiza. Sal B is used widely
to treat cardiovascular diseases [21]. Recent data have
shown that Sal B protects the myocardium and car-
diovascular system through: inhibition of expression
of matrix metalloproteinase-9 and fibrosis [22]; inhib-
ition of adenosine diphsophate-induced platelet aggre-
gation [23]; suppression of expression of intercellular
adhesion molecule-1 in tumor necrosis factor-α-
treated endothelial cells [24]. Evidence also suggests
that Sal B inhibits autophagy and protects starving
cardiomyocytes [25].
In summary,both miR-30a and Sal B have a close rela-
tionship with cardiovascular disease through autophagy.-
but few studies have focused on the mechanism of
action of miR-30a in the cardioprotective effects of Sal
B. We hypothesized that Sal B may have a more import-
ant role in cardiovascular disease than currently thought.
Hence, to examine the involvement of the miR-30a/
PI3K/Akt pathway in ischemic cardiovascular injury and
the potential protective effect of Sal B in terms of au-
tophagy, we used an in vitro model of I–R to observe
the effect of Sal B.
Methods
Reagents and antibodies
Reagents associated with cell culture were obtained from
Invitrogen (Carlsbad, CA, USA). Cell Counting Kit 8
(CCK-8, CK04) was purchased from Dojindo Laborator-
ies (Kumamoto, Japan). Lactic acid dehydrogenase
(LDH) Cytotoxicity Assay kit was obtained from Gen
Way Biotech (San Diego, CA, USA). LY294002 (PI3K in-
hibitor) was purchased from Sigma–Aldrich (Saint
Louis, MO, USA). A double-stranded pre-miR-30a
mimic and a single-strand inhibitor were obtained from
GenePharma (Shanghai, China). Pre-miR-30a is chem-
ically modified to guide the selection and stability of
strands. The negative control for pre-miRs was used as a
non-sensical oligonucleotide control. Antibodies against
beclin-1, LC3-II, p-Akt (Ser 473) and total-Akt were
purchased from Cell Signaling Technology (Danvers,
MA, USA). Sal B (purity ≥ 98 %) was obtained from the
National Institutes for Food and Drug Control
(Beijing, China).
Cell culture and miR-30a transfection
One-day-old male C57BL/6 J mice (certificate no.
SCXK (Jing) 2012-0001) were purchased from Vital
River Laboratory Animal Technology (Beijing, China).
All experiments with animals were performed in ac-
cordance with China Academy of Chinese Medical
Sciences Guide for Laboratory Animals that conforms
to the Guide for the Care and Use of Laboratory Ani-
mals published by the U.S. National Institutesof
Health. The protocol was approved by the Institute’s
Animal Care and Use Committee of Experimental
Animal Research Institute, China Academy of Chinese
Medical Sciences where there were veterinarians and
scientists involved who are qualified in the evaluation
of animal ethical issues.
To acquire primary myocardial cells, separated ven-
tricular tissue was minced into small pieces followed by
digestion with 0.05 g/L collagenase II–0.625 g/L trypsin
at 37 °C for 20 min. The suspension was filtered through
a 200-μm mesh sieve and resuspended in myocardial
cell-complete medium (Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10 % fetal bovine
serum (FBS), 1 × 105 U/L penicillin, 1 × 105 U/L strepto-
mycin sulfate, pH 7.2. The unattached cells were plated
at 5 × 104 cells/cm2 on appropriate culture dishes or
plates. The subsequent experiments were performed 48-
72 h after plating, when the cardiomyocytes of mice
were cultured to 70-80 % confluence.miR-30a inhibitor
(100 nmol/L), miR-30a mimics (100 nmol/L) or negative
control (100 nmol/L) were transfected into myocardial
cells for 24 h using siRNA-MATE (GenePharma)
according to manufacturer instructions.
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I–R and treatment with Sal B
An oxygen–glucose deprivation (OGD) model was used
to mimic ischemia according to the method established
by Wang et al. [21]. Briefly, myocardial culture medium
was substituted with glucose-free DMEM. Culture flasks
(or plates) were placed in a sealed tank with persistent
low flow (1.5 L/min) of a mixture of 95 % N2 and 5 %
CO2. The tank was placed in an incubator at 37 °C for
2 h to mimic ischemia. After ischemia 2 h, mimic reper-
fusion injury was achieved by changing the medium in
normal culture fluid and exposing cells to ambient air,
and the cells were maintained for another 2,6,and 24 h.
Drug treatment involved cells being incubated with
25 μM, 50 μM and 100 μM Sal B at the onset of ische-
mia and reperfusion. Treatment of myocardial cells with
100 μM Sal B for 24 h under normal culture conditions
did not demonstrate toxicity (data not shown).
Real-time polymerase chain reaction (PCR)
About 106 cells were added to 1 mL Trizol (Invitrogen,
Carlsbad, CA, USA) to extract total RNA. Total RNA
(1 μg) was taken for reverse transcription using a Super-
Script III Reverse Transcriptase kit with an oligo (dT) pri-
mer (Invitrogen). Expression of mature mouse miRNAs
was determined by a stem-loop real-time PCR system
using Maxima SYBR Green quantitative PCR Master Mix
(Fermentas, Ontario, Canada) and StepOne Sequence De-
tector (Applied Biosystems, Foster City, CA, USA). The
mmu-miR-30a-F2 primer was 5′-ACAGCCTGTAAA-
CATCCTCG -3′ and the mmu-miR-30a-RT primer was
5′-GTCGTATCCAGTGCAGGG TCCGAGGTATTCGC
ACTGGATACGACTTCCAGT-3′. PCR primers for U6
were 5′-CTCGCTTCGGCAGCACATATACT-3′ and 5′-
ACGCTTCACGAATTT GCGTGTC-3′. The universal
primer downstream (mir-R2) was 5′-TCGTATCCAGT
GCAGGGTC-3′. Data were normalized from control or
I-R group (100 %) and expressed as a percentage of the
control or I-R group.
Western blotting
Expression of beclin-1, LC3-II, p-Akt and total-Akt in
myocardial cells was detected by western blotting Pro-
tein samples were extracted from cardiac myocyte. Prep-
aration of protein samples consisted of several steps,
including splitting, centrifugation and boiling. Protein
samples (20 μg) were fractionated by sodium salt (SDS)-
Polyacrylamide gel electrophoresis (PAGE) (10 % or
12 % polyacrylamide gels), transferred to a polyvinyli-
dene difluoride (PVDF) membrane and then blocked in
5 % bovine serum albumin and prepared in a Tris-
buffered saline (TBS) for 1 h at room temperature. The
membranes were incubated with specific antibodies
(1:1000 dilution) against beclin-1, LC3-II, p-Akt, total-
Akt and β-actin (Cell Signaling Technology, USA). Blots
were detected using horseradish peroxidase-conjugated
secondary antibody (1:2000 dilution; Santa Cruz Biotech-
nology, CA, USA) for 1 h at room temperature. After
washing, the immunoreactive protein bands were devel-
oped by an Enhanced chemiluminescencekit (Pierce,
Rockford, IL, USA) and the resulting membranes were im-
aged using the gel imaging system (BIO-RAD). The test of
each protein was repeated 3 times. Data were normalized
from control or I-R group (100 %) and expressed as a per-
centage of the control or I-R group.
CCK-8 assay
Myocardial cells (1 × 103 cells per well) were seeded on
96-well plates. The cells were either treated with I-R
only, or treated with addition of Sal B. Normal cultured
microglial cells without any treatment were used as con-
trol. Cell viability was evaluated with the CCK-8 assay,
according the instruction of the manufacture . In brief,at
the end of I–R, the medium in 96-well culture plates
was changed to DMEM/F12 to avoid background inter-
ference. CCK-8 (10 μL) was added to each well followed
by incubation for 2 h at 37 °C. A microplate reader was
used to measure the optical-density value at 450 nm.. In
control groups and experimental groups, 6 wells cells
were observed and experiment was repeated 3 times.
Data were normalized from control (100 %) and
expressed as a percentage of the control group.
LHD assay
For measurement of LDH leakage, he ischemia and reper-
fusion supernatants were collected. LDH activities were
measured using the enzymatic reaction kinetics monitoring
method according to the manufacturer’s instructions. The
total LDH activity was obtained from adding LDH activities
in the ischemia and reperfusion supernatants and the cell
lysate together. Rate of LDH leakage was expressed using
the following equation: Rate of LDH leakage = (OD value of
the supernatant of the medium/OD value of the total
cells) × 100 %. Data were normalized from control (100 %)
and expressed as a percentage of the control group.
Statistical analysis
Data were expressed as mean ± standard deviation (SD).
Differences between experimental groups were examined
by one-way analysis of variance (ANOVA), and means of
two groups were compared using Student’s t-test (paired,
2-tailed) by SPSS 18.0 software. P < 0.05 was considered
significant.
Results
MiR-30a expression decreases in myocardial cells with an
I–R model and Sal B increases miR-30a expression
Real-time PCR was first conducted to disclose the differ-
ence in miR-30a level between normal cultured cells and
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ischemic myocardial cells. Compared with the control
group,the miR-30a level was reduced greatly in myocar-
dial cells with I–R injury in a time-dependent manner,
with the level in the I–R 24 h group (47.26 ± 21.33 %)
being significantly different (P < 0.05; Fig. 1a). Compared
with the I-R group, the miR-30a level could be improved
by Sal B in a dose-dependent manner, with 50 μM
(171.51 ± 43.49 %) and 100 μM groups (213.41 ±
85.68 %) showing remarkable changes (P < 0.05; Fig. 1b).
According to the results shown above, we confirmed the
I–R time to be 24 h and the dose of Sal B to be 50 μM.
Sal B inhibits the autophagy of myocardial cells induced
by I–R
Based on the results of the time-course and dose-course
experiments mentioned above, This study investigated
the regulatory effects of 50 μM Sal B on autophagy in
myocytes subjected to I–R for 24 h. Compared with the
control group in this experiment, immunoblot analyses
showed that I–R caused an increase in endogenous
beclin-1 (218.81 ± 18.70 %, P < 0.01, Fig. 2a) and LC3-II
(208.93 ± 39.19 %, P < 0.05, Fig. 2b), thereby suggesting
increased autophagy. This increase was suppressed by
Sal B, which suggested that increased autophagy in myo-
cardial cells under I–R could be blocked by Sal B, with
relative densities of beclin-1 and LC3-II of 117.47 ±
12.48 % and 107.52 ± 30.38 %, respectively.
Sal B improves cell viability and reduces rate of LDH
leakage of I–R-injured myocardial cells
Given that autophagy is non-selective and serves as a
“double-edged sword” for ischemic injury in the heart,
we next ascertained if the inhibitory effect of Sal B on
myocardial autophagy was beneficial. A combination of
cell viability and assay was used to measure the rate of
LDH leakage, which are regarded as reliable markers of
cellular injury. Figure 3a and b showed that compared
with the control group,after cardiomyocytes were sub-
jected to I–R for 24 h, significant suppression of cell via-
bility (90.02 ± 1.87 %, P < 0.01) and LDH release were
induced (217.22 ± 66.51 %, P < 0.01), which were recov-
ered significantly by Sal B (94.41 ± 2.76 %, P < 0.01;
Fig. 1 a MicroRNA-30a (miR-30a) level decreases in myocardial cells with I–R injury detected by real time-polymerase chain reaction
(RT-PCR). I–R-2 h, I–R-6 h and I–R-24 h denote subjection of myocardial cells to reperfusion for 2, 6, and 24 h followed by ischemic injury,
respectively. b Sal B increases miR-30a expression in a dose-dependent manner.. Values are the mean ± SD from 5 wells per group.
*P <0.05 vs control or I–R-24 h group
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149.05 ± 24.35 %, P <0.05). These findings suggested that
the inhibitory effect of Sal B on myocardial autophagy
was beneficial for I–R-injured myocardial cells.
Sal B-mediated anti-autophagy effect on cardiac cells is
reversed by a miR-30a inhibitor
Beclin-1 expression was evaluated to further confirm the
mechanism of Sal B down-regulation of miR-30a-
mediated cardiac autophagy (Fig. 4). Compared with the I-
R group Sal B could significantly decrease beclin-1 expres-
sion (54.19 ± 9.96 %, P <0.05), suggesting suppression of
autophagy. However, compared with the Sal B group,
beclin-1 expression in the Sal B with a miR-30a inhibitor
group increased by 49.8 %, whereas the scramble sequence
had no significant effect on Sal B-induced cardiac protec-
tion against autophagy. These data suggested that Sal
B-mediated miR-30a expression might protect myocardial
cells against I–R injury, probably through regulation of
autophagy.
Inhibition of PI3K expression abrogates protection by Sal
B-induced miR-30a expression
To demonstrate the direct link between the PI3K/Akt
signaling pathway and miR-30a expression induced by
Sal B, PI3K expression was inhibited using the PI3K in-
hibitor LY294002(5 μM), which was given for the first
15 min of I–R. Compared with the I-R group,treatment
with Sal B could reduce beclin-1 expression (66.237 ±
11.22 %, P < 0.05; Fig. 5a) and induce p-Akt expression
(176.954 ± 21.51 %, P < 0.01; Fig. 5b). No difference was
observed in total Akt expression under different condi-
tions (Fig. 5b). Overexpression of miR-30a could further
increase expression of p-Akt to 226.253 ± 20.50 % and
reduce beclin-1 expression to 45.505 ± 6.91 %. However,
the PI3K inhibitor LY294002 could abrogate the cardio-
protection of miR-30a against I–R.
Discussion
Sal B is a natural compound used for the treatment of
ischemic heart disease. Most studies of Sal B have fo-
cused on its ability to scavenge reactive oxygen species
[26], inhibition of adherence between leukocytes and
endothelial cells [27] and inflammation suppression [28].
Recent studies have revealed that miRNAs are involved
in physiologic and pathologic processes in the cardiovas-
cular system. The present study is the first to demon-
strate that miR-30a expression can be mediated by Sal B,
which plays an important in protection against cardiac
I–R injury in vitro. The results presented here indicate
that the potential signal pathway of Sal B inhibited miR-
30a mediated cardioprotection might be achieved by tar-
geting PI3K/Akt signaling pathway.
A subset of miRNAs are expressed abundantly in car-
diac tissue, and have important roles in numerous car-
diac diseases such as heart failure [29], myocardial
fibrosis [30] and ischemic heart disease [31]. In diseases
of the cardiovascular system, miR-30a plays an import-
ant part in regulation of autophagy through beclin-1
protein during myocardial injury induced by angiotensin
II [32]. miR-30a expression has been reported to be
Fig. 2 Sal B suppresses the levels of the autophagy-related proteins (a) beclin-1 and (b) LC3-II induced by I–R-24 h. Values are the mean ± SD
from 3 wells per group. * P <0.05 vs control; **P <0.01 vs control; # P < 0.05 vs I–R-24 h group; ## P <0.01 vs I–R-24 h group
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increased in cultured myocardial cells [6] and in circu-
lating plasma from patients with acute myocardial in-
farction [33]. In contrast, using quantitative real-time
RT-PCR analyses, we found that miR-30a expression was
down-regulated by I–R at 2, 6 and 24 h in a time-
dependent manner. Specifically, the miR-30a level in
myocardial cells subjected to I–R for 24 h appeared to
decrease significantly. This finding suggested that reper-
fusion could suppress the miR-30a level (i.e., a high level
of autophagy). This phenomenon could be suppressed
by Sal B, which has not been reported before.
Several studies have focused on miR-30a target genes
and their involvement in pathophysiologic processes. It
has been demonstrated that miRNA-30a can bind dir-
ectly with the 3′-UTR of beclin-1 mRNA and promote
degradation of its mRNA [34]. Beclin-1 is highly hom-
ologous with yeast autophagy-related gene 6 (Apg6/
Vps30), which is essential for the induction and regula-
tion of autophagy [35]. Studies have demonstrated that
upregulation of beclin-1 expression promotes autophagic
activity [36, 37]. Valentim et al. [38]. showed that
inhibition of autophagy by genetic and pharmacologic
inhibition of beclin-1 reduced death of cardiomyocytes
subjected to simulated I–R. Given the increase in miR-
30a expression by Sal B, we next observed that Sal B
could suppress beclin-1 expression, suggesting inhibition
of autophagy. LC3 is processed from LC3-I (16 kDa) to
LC3-II (14 kDa), which is recruited to autophagosomes,
and the increase in the LC3-II/I ratio is an indicator of
up-regulated autophagy [39]. In addition to beclin-1, this
study also observed that Sal B inhibited LC3-II expres-
sion, suggesting restriction of autophagic activity. The
inhibition of autophagy induced by Sal B was induced by
increases in miR-30a expression.
Whether autophagy has a protective or lethal role in the
ischemic myocardium is controversial. In recent years, the
regulation and contribution of the autophagic process to
cell metabolism has been characterized in great detail. Sev-
eral studies reported a role for autophagy in programmed
cell death in heart disease. Paradoxically, some studies re-
ported that in the case of myocardial ischaemic injury, au-
tophagy causes cell survival, whereas the reperfusion injury
Fig. 3 a Bar graphs show that Sal B increases the viability of cells subjected to I–R-24 h as determined by the CCK-8 assay. b Bar graphs show
that Sal B reduces the rate of LDH leakage in the culture media of myocardial cells. Data are the mean ± SD from 6 wells per group. ** P <0.01 vs
control; # P <0.05 vs I–R-24 h group; ## P <0.01 vs I–R-24 h group
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causes cell death. It has been demonstrated that excessive
autophagy leads to cell death. Thus, the extent of autoph-
agy appears to be critical for determining whether it will
play a protective or harmful role, This study wanted to
know if suppression of autophagy by Sal B was beneficial
for I–R-injured myocardial cells. Cell viability and LDH
leakage from cells are used widely as reliable markers of
cellular injury. The degree of LDH leakage is closely related
to cardiomyocyte necrosis [40, 41]. Thus, the protective
effects of Sal B on I–R-induced cardiomyocyte injury
according to cell viability and LDH leakage was explored
the protective effects of Sal B on I–R-induced cardiomyo-
cyte injury according to cell viability and LDH leakage.
Suppression of autophagy by Sal B was beneficial for sur-
vival of I–R-injured cells, as characterized by increased cell
viability and reduced rate of LDH leakage. Next, we wished
to ascertain if miR-30a was involved in the Sal B-mediated
anti-autophagy effects on cardiomyocytes. After transfer-
ring a miR-30a inhibitor or the scramble sequence into car-
diomyocytes, we found that the miR-30a inhibitor (but not
the scramble sequence) could attenuate Sal B-induced car-
dioprotection against the autophagy induced by simulated
I–R injury. Taken together, we deduced that Sal B protects
cardiomyocytes through miR-30a upregulation-mediated
inhibition of autophagy.
Consequently, this study will continue to identify the
role of the PI3K/Akt signaling pathway in miR-30a-
mediated autophagy after I–R injury in future studies.
LDH release and cell viability was shown that I–R dam-
aged myocardial cells and that, when I–R occurred, au-
tophagy was increased as characterized by up-regulation
of expression of beclin-1 and LC3-II. Sal B could reduce
beclin-1 expression, and miR-30a mimics reduced
beclin-1 expression further. After transferring a miR-30a
inhibitor into the myocardium to “silence” expression of
endogenous miR-30a, beclin-1 expression was increased,
suggesting that miR-30a can protect myocardial cells
through suppression of autophagy. When the PI3K in-
hibitor LY294002 was added into the system, beclin-1
expression was increased, suggesting that it abrogated
the cardioprotective properties of miR-30a against I–R.
From the viewpoint of autophagy,this study demon-
strated (indirectly) that a PI3K inhibitor could abrogate
the cardioprotective properties of miR-30a. Furthermore,
inhibition of PI3K expression at the time of reperfusion
abrogated p-Akt expression and the anti-autophagy ef-
fect of miR-30a induced by Sal B. Taken together, these
data demonstrate that Sal B can alleviate I–R-injured
myocardial cells through miR-30/PI3K/Akt pathway-
mediated suppression of autophagy.
Fig. 4 Sal B reduces the expression of beclin-1, which is reversed by a miR-30a inhibitor. Values are the mean ± SD from 3 wells per group.
* P <0.05 vs I–R-24 h group; # P <0.05 vs Sal B group; % P <0.05 vs miR-30a inhibitor + Sal B group
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Conclusion
In summary, our data suggest that miR-30a has a vital
role in Sal B-induced cardioprotection. Upregulation of
endogenous miR-30a expression induced by Sal B can
alleviate I–R-induced myocardial autophagy, and the
mechanism of action could involve regulation of the
PI3K/Akt signaling pathway.
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